JANX241220P65000
- 0.00
- 0.000.00%
Janux Therapeutics Newsroom
Janux Therapeutics Initiated With an Outperform at Leerink
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Janux Therapeutics Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $79
Innovative TRACTr Platform and Promising Prospects for Janux Therapeutics: An Analysis of JANX007's Potential in Prostate Cancer Treatment
10 Health Care Stocks Whale Activity In Today's Session
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
Janux Therapeutics Analyst Ratings
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Cantor Fitzgerald Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Amicus (FOLD) and Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (JANX) Receives a Buy From Cantor Fitzgerald
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $63
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Raises Target Price to $82
Janux Therapeutics GAAP EPS of -$0.51 Misses by $0.13, Revenue of $0.44M Misses by $1.23M
TD Cowen Maintains Janux Therapeutics(JANX.US) With Buy Rating
Promising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics' JANX007 in MCRPC Treatment
Janux Therapeutics | 10-Q: Q3 2024 Earnings Report
Janux Therapeutics | 8-K: Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights